Previous Close | 66.31 |
Open | 66.04 |
Bid | 67.66 x 900 |
Ask | 67.67 x 1000 |
Day's Range | 65.81 - 66.37 |
52 Week Range | 60.47 - 76.56 |
Volume | |
Avg. Volume | 6,287,378 |
Market Cap | 204.162B |
Beta (5Y Monthly) | 0.17 |
PE Ratio (TTM) | 34.66 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.45 (2.20%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AZN
AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
High drug prices in the United States have been the subject of growing political scrutiny for years. Senator Bernie Sanders and other lawmakers in January criticized the top four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals and GSK — over high prices.